Entrada Therapeutics Inc (TRDA)
18.00
+0.24
(+1.38%)
USD |
NASDAQ |
Nov 05, 11:37
Entrada Therapeutics Free Cash Flow: -18.50M for June 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2024 | -18.50M |
| March 31, 2024 | -93.90M |
| December 31, 2023 | 134.19M |
| September 30, 2023 | 111.17M |
| June 30, 2023 | 108.81M |
| March 31, 2023 | 126.64M |
| Date | Value |
|---|---|
| December 31, 2022 | -96.67M |
| September 30, 2022 | -90.52M |
| June 30, 2022 | -77.11M |
| March 31, 2022 | -67.78M |
| December 31, 2021 | -55.44M |
Free Cash Flow Range, Past 5 Years
-96.67M
Minimum
Dec 2022
134.19M
Maximum
Dec 2023
-1.738M
Average
-55.44M
Median
Dec 2021
Free Cash Flow Benchmarks
| Fulcrum Therapeutics Inc | -12.62M |
| Sarepta Therapeutics Inc | -527.92M |
| Catalyst Pharmaceuticals Inc | 114.96M |
| Vertex Pharmaceuticals Inc | -1.426B |
| Regenxbio Inc | -194.72M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 39.83M |
| Cash from Investing (Quarterly) | -24.38M |
| Cash from Financing (Quarterly) | 101.37M |
| Free Cash Flow Per Share (Quarterly) | 1.092 |
| Free Cash Flow to Equity (Quarterly) | 38.79M |
| Free Cash Flow to Firm (Quarterly) | 38.79M |
| Free Cash Flow Yield | -2.97% |